Efficacy and safety of pregabalin for treating painful diabetic peripheral neuropathy: a meta‐analysis

Zhang, S.-S.; Wu, Zhi‐Yong; Zhang, L.-C.; Zhang, Z.; Chen, R.-P.; Huang, Yue; Chen, H.

doi:10.1111/aas.12420

Cited by 35 publications

(29 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Regarding specific conditions, the Cochrane Collaboration [48]. Pregabalin was found to be efficacious compared with placebo in improving pain scores (mean difference -0.79) and in the proportion of patients achieving a reduction of ≥50% in pain intensity (RR 1.54) in patients with painful diabetic peripheral neuropathy [73]. Gabapentin and pregabalin have not been shown to be effective in ameliorating pain in patients with HIV-associated neuropathy [74].…”

Section: Neuropathic Painmentioning

confidence: 99%

Alpha₂delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use

Calandre

Rico‐Villademoros

Slim

2016

Expert Review of Neurotherapeutics

187

128

View full text Add to dashboard Cite

The first two alphadelta ligands - gabapentin (GBP) and pregabalin (PGB) - were initially synthesized as antiepileptics; however, they were later also found to be useful for the treatment of additional conditions. Areas covered: Relevant publications describing potential underlying mechanisms, clinical pharmacokinetics/pharmacokinetics, and clinical efficacy and safety of these drugs in various disease conditions were searched in PubMed and Scopus and included in this review. Expert commentary: GBP and PGB are effective for the treatment neuropathic pain, fibromyalgia and epilepsy; in addition, they may be useful for the reduction of postoperative pain. PGB is also effective for the treatment of generalized anxiety disorder and GBP for the treatment of restless legs syndrome. GBP may be considered a treatment option for pain associated with Guillain-Barré Syndrome and phantom limb and for the management of uremic pruritus. Mirogabalin (MGB), recently developed, is being investigated for the treatment of peripheral neuropathic pain and fibromyalgia, showing promising results in patients with diabetic peripheral neuropathy. Their most frequent adverse reactions are of neuropsychiatric nature and include fatigue, dizziness, sedation, somnolence, and ataxia; peripheral edema and weight gain are also frequently described. Pharmacokinetic interactions are scarce; however, pharmacodynamic interactions have been described in association with drugs with CNS-depressant effects.

show abstract

Section: Neuropathic Painmentioning

confidence: 99%

Alpha₂delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use

Calandre

Rico‐Villademoros

Slim

2016

Expert Review of Neurotherapeutics

187

128

View full text Add to dashboard Cite

show abstract

“…23 In clinical trials of patients with peripheral neuropathic pain, gabapentinoids have consistently demonstrated significant benefit. 24-26 However, only a minority of patients achieved substantial pain relief, with many not responding. Patients with CIBP generally have multiple serious morbidities and a more complex array of factors contributing to their hypersensitivity, as a result of immunologic responses to the cancer.…”

Section: Discussionmentioning

confidence: 99%

Randomized Double-Blind Trial of Pregabalin Versus Placebo in Conjunction With Palliative Radiotherapy for Cancer-Induced Bone Pain

Fallon

Hoskin

Colvin

et al. 2016

JCO

View full text Add to dashboard Cite

PurposeCancer-induced bone pain (CIBP) affects one third of patients with cancer. Radiotherapy remains the gold-standard treatment; however, laboratory and clinical work suggest that pregabalin may be useful in treating CIBP. The aim of this study was to examine pregabalin in patients with CIBP receiving radiotherapy.Patients and MethodsA multicenter, double-blind randomized trial of pregabalin versus placebo was conducted. Eligible patients were age ≥ 18 years, had radiologically proven bone metastases, were scheduled to receive radiotherapy, and had pain scores ≥ 4 of 10 (on 0-to-10 numeric rating scale). Before radiotherapy, baseline assessments were completed, followed by random assignment. Doses of pregabalin and placebo were increased over 4 weeks. The primary end point was treatment response, defined as a reduction of ≥ 2 points in worst pain by week 4, accompanied by a stable or reduced opioid dose, compared with baseline. Secondary end points assessed average pain, interference of pain with activity, breakthrough pain, mood, quality of life, and adverse events.ResultsA total of 233 patients were randomly assigned: 117 to placebo and 116 to pregabalin. The most common cancers were prostate (n = 88; 38%), breast (n = 77; 33%), and lung (n = 42; 18%). In the pregabalin arm, 45 patients (38.8%) achieved the primary end point, compared with 47 (40.2%) in the placebo arm (adjusted odds ratio, 1.07; 95% CI, 0.63 to 1.81; P = .816). There were no statistically significant differences in average pain, pain interference, or quality of life between arms. There were differences in mood (P = .031) and breakthrough pain duration (P = .037) between arms. Outcomes were compared at 4 weeks.ConclusionOur findings do not support the role of pregabalin in patients with CIBP receiving radiotherapy. The role of pregabalin in CIBP with a clinical neuropathic pain component is unknown.

show abstract

“…The efficacy and safety of pregabalin for pDPN treatment have been established in multiple studies conducted in the US, Europe, Japan, and Korea . A recently concluded pooled analysis of 2056 patients further confirmed the efficacy of pregabalin for pDPN treatment . In China, pregabalin is approved for PHN treatment .…”

Section: Introductionmentioning

confidence: 92%

Efficacy and safety of pregabalin for painful diabetic peripheral neuropathy in a population of Chinese patients: A randomized placebo‐controlled trial

Liu

et al. 2017

Journal of Diabetes

View full text Add to dashboard Cite

show abstract

Efficacy and safety of pregabalin for treating painful diabetic peripheral neuropathy: a meta‐analysis

Abstract: Our meta-analysis indicates that pregabalin is more effective than placebo for managing DPN-associated pain and other symptoms that reduce quality of life. The drug is also reasonably well tolerated.

Cited by 35 publications

References 36 publications

Alpha₂delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use

Alpha₂delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use

Randomized Double-Blind Trial of Pregabalin Versus Placebo in Conjunction With Palliative Radiotherapy for Cancer-Induced Bone Pain

Efficacy and safety of pregabalin for painful diabetic peripheral neuropathy in a population of Chinese patients: A randomized placebo‐controlled trial

Contact Info

Product

Resources

About

Efficacy and safety of pregabalin for treating painful diabetic peripheral neuropathy: a meta‐analysis

Abstract: Our meta-analysis indicates that pregabalin is more effective than placebo for managing DPN-associated pain and other symptoms that reduce quality of life. The drug is also reasonably well tolerated.

Cited by 35 publications

References 36 publications

Alpha2delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use

Alpha2delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use

Randomized Double-Blind Trial of Pregabalin Versus Placebo in Conjunction With Palliative Radiotherapy for Cancer-Induced Bone Pain

Efficacy and safety of pregabalin for painful diabetic peripheral neuropathy in a population of Chinese patients: A randomized placebo‐controlled trial

Contact Info

Product

Resources

About

Alpha₂delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use

Alpha₂delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use